Enliven Therapeutics Inc
ELVNHealthcare|Biotechnology|USA
$51.09
-1.09 (-2.09%)
Tangible Book
$7.45
Upcoming Data Readouts (3)
Jan 2027
Est. completion
P1HER2-positive Breast Cancer
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT06328738n=275
Dec 2027
Est. completion
P1Chronic Myeloid Leukemia
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377n=250
Jan 2028
Est. completion
P1CML (Chronic Myelogenous Leukemia)
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
NCT06787144n=21
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.